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a  b  s  t  r  a  c  t
PAX  transcription  factors  are  key  players  in  the  development  of different  tissues  and  organs.  At  the
cellular  level  they are  involved  in  regulating  lineage  commitment  and  differentiation.  Interference  with
these tightly  regulated  functions  of  PAX  proteins  is  associated  with  developmental  abnormalities  and
tumorigenesis  of  several  types  of  cancer.  As  a result  of aberrant  PAX  protein  activity,  either  by gain-  or
loss  of  function  mechanisms,  affected  cells are  kept  in a  proliferative  state  by blocking  their  terminal
differentiation.  PAX  proteins  with  a gain-of-function  role  in  cancer  are  active  in  the  proliferative  state
of  cells  and  have  to be  downregulated  before  they can  complete  the  differentiation  process.  Such  PAX
proteins  are  usually  activated  in  malignancies  by  chromosomal  translocations  generating  fusions  with
strong  transcriptional  activators.  PAX  proteins  with  tumor  suppressor  activity  are  actively  driving  the
differentiation  process  and  are  necessary  for the  exit  from  the  proliferative  state.  In cancer,  a diverse  set
of mutational  mechanisms  is  involved  in reducing  their  activity.
Here, we  discuss  the  characteristics  of mutant  PAX  proteins  in  different  types  of cancer  including
alveolar rhabdomyosarcoma,  biphenotypic  sinonasal  sarcoma,  thyroid  cancer  and leukemia,  with  special
focus on their  role  in  interference  with  normal  differentiation  pathways  of the  cell  lineage  involved.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
PAX proteins play important roles during embryogenesis and
are crucial for the development of various tissues and organs.
∗ Corresponding author at: Department of Oncology, University Children’s Hos-
pital, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland.
E-mail address: beat.schaefer@kispi.uzh.ch (B.W. Schäfer).
Hence, aberrant activity of different PAX proteins is associated with
several developmental defects. In the adult organism, PAX pro-
teins remain expressed mainly in stem/progenitor cell populations
but also in some mature cells and are functionally involved in tis-
sue regeneration and maintenance [1]. At the cellular level, PAX
proteins are important regulators of lineage commitment and dif-
ferentiation. This functional role as molecular switches between
proliferative and differentiated states of cells characterizes PAX
proteins as potential tumorigenic proteins. Indeed, in the last two
http://dx.doi.org/10.1016/j.semcdb.2015.09.011
1084-9521/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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decades it became evident that aberrant PAX protein activity is
causally involved in tumorigenesis of different malignancies. Most
of the nine PAX protein family members have been associated
with a role in cancer [2]. One type of mechanism by which PAX
proteins contribute to tumorigenesis is the expression of inap-
propriate levels of wildtype proteins, which plays an important
role in numerous tumor types. These quantitative disturbances are
beyond the scope of this review and the reader is referred to other
reviews in the ﬁeld [2–4]. Here, we speciﬁcally focus on genetic
aberrations of PAX proteins involved in tumorigenesis and dis-
cuss a model that correlates aberrant PAX protein activity with
permissive cellular states present in affected cell lineages. In this
context both gain and loss of function roles of PAX proteins have
been described. The prime examples for this yin and yang func-
tion of PAX proteins are PAX3/7 in alveolar rhabdomyosarcoma and
biphenotypic sinonasal sarcoma, PAX8 in thyroid cancer and PAX5
in B-cell acute lymphoblastic leukemia, which we  will discuss in
detail.
2. Gain of function roles of PAX proteins in cancer
2.1. PAX3 and PAX7
2.1.1. PAX3 and PAX7 in normal development
PAX3 and PAX7 are important regulators of neural tube, neural
crest and skeletal muscle development. Based on the characteris-
tics of the tumors expressing aberrant PAX3/7 proteins, of special
interest here are the roles of PAX3 and PAX7 in the myogenic and
neural crest-derived lineages.
During embryonic development the process of myogenesis
starts with embryonic progenitors in the dermomyotomal part of
the somites (for review and details see [5]). These cells migrate
to reach the ﬁnal anatomic location where they terminally dif-
ferentiate or form a heterogeneous pool of stem and committed
cells called satellite cells. Both PAX3 and PAX7 are expressed in
the dermomyotome, however, they fulﬁll different functions dur-
ing myogenesis. PAX3 but not PAX7 is expressed in long-range
migrating cells which form the initial limb musculature and PAX3
deﬁcient mice do not develop limb or diaphragm muscles [6–8].
PAX7 appears to be dispensable for embryonic muscle develop-
ment and instead is responsible for renewal and maintenance of
the satellite cell pool [9,10].
At the cellular level, embryonic progenitors give rise to acti-
vated committed cells (myoblasts). The subsequent differentiation
process then leads to myocytes which ﬁnally fuse to form multinu-
cleated myotubes (Fig. 1) [11]. A genetic hierarchy regulates these
different steps, initiated by the upstream regulators sine oculis-
related homeobox 1 and 4 (Six 1 and −4), followed by activation of
PAX3 and PAX7 which direct expression of the downstream myo-
genic regulatory factor (MRF) family (Myf5, MyoD, Myogenin and
Myf6 (Mrf4)). PAX3 and PAX7 are speciﬁcally active during early
stages of lineage commitment and are downregulated to allow ter-
minal differentiation into muscle cells (Fig. 1) [12,13]. Maintenance
of PAX3 and PAX7 expression prevents differentiation of myoblasts
and satellite cells, respectively [14,15].
PAX3 also has a prominent role in the neural crest lineage
(for review see [16]). Neural crest cells give rise to a wide range
of derivatives including cells of the peripheral nervous system
(PNS), melanocytes, endocrine cells and mesenchymal cells able
to differentiate into connective, adipose, bone, cartilage tissues and
pericytes [17]. In the mouse, PAX3 is ﬁrst detected at E8.5 in the dor-
sal neuroepithelum and later, in neural crest cells of the developing
PNS, the neural crest-derived craniofacial mesenchyme and the
migratory cardiac neural crest cells [18]. Similar to the myogenic
Fig. 1. Expression of PAX3/7 during skeletal muscle development and PAX5 during B-cell development and stages of gain and loss of their activities in associated tumors.
In  the myogenic lineage, PAX3/7 expression is induced in muscle progenitor cells and is involved in commitment to the myogenic lineage. Before terminal differentiation is
executed, PAX3/7 is downregulated. Aberrant activity of PAX3/7-FOXO1 blocks differentiation and promotes tumorigenesis. During B cell development, PAX5 expression starts
at  the pro-B cell stage and is involved in commitment to the B cell lineage. It is stably expressed throughout B cell development and downregulated at the initiation of plasma
cell  differentiation. Loss of PAX5 activity blocks differentiation and acts as cooperative hit in tumorigenesis of B-ALL. HSC, hematopoietic stem cells, LMPP, lymphoid-primed
multipotent progenitors, CLP, common lymphoid progenitors.
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Table 1
PAX fusion proteins in cancer.
Tumor type Fusion protein Frequency [%] Function of partner protein Effects beyond PAX Ref.
Alveolar rhabdomyosarcoma PAX3-FOXO1 60 Transcription factor [122]
PAX7-FOXO1 20 Transcription factor [123]
PAX3-FOXO4 Single case Transcription factor [22]
PAX3-NCOA1 Recurrent Nuclear receptor coactivator [24,25]
PAX3-NCOA2 Recurrent Nuclear receptor coactivator [24]
PAX3-INO80D Single case Regulatory component of INO80
chromatin remodeling complex
[23]
Biphenotypic sinonasal
sarcoma
PAX3-MAML3 79 Transcriptional coactivator for Notch
intracellular domain
[78]
B-ALL PAX5-ETV6 Up to 1 Transcription factor [100,106,124,125]
PAX5-PML Recurrent Scaffolding protein for PML  nuclear
bodies
Inhibition of PML
functions
[111,126]
PAX5-FOXP1 Recurrent Transcriptional repressor [100,106]
PAX5-ZNF521 Single case Transcription factor [100]
PAX5-ELN Recurrent Extracellular matrix protein [106,107]
PAX5-AUTS2 Recurrent not known [106,127]
PAX5-C20orf112 Recurrent not known [105,124,127]
PAX5-JAK2 Recurrent Non-receptor tyrosine kinase Activation of JAK-STAT
pathway
[105,106,109]
PAX5-BRD1 Single case Component of the MOZ/MORFH3
acetyltransferase complex
[105]
PAX5-POM121 Recurrent Component of the nuclear pore
complex
[105,106]
PAX5-HIPK1 Single case Serine/threonine kinase – corepressor
for homeodomain TFs
[105]
PAX5-DACH1 Single case Transcription factor [105]
PAX5-LOC392027 Single case Pseudogene [124]
PAX5-SLCO1B3 Single case Organic anion transporter [124]
PAX5-ASXL1 Recurrent Nuclear receptor coactivator [124]
PAX5-KIF3B Single case Component of kinesin motor complex [124]
PAX5-DACH2 Single case Transcription factor [106]
PAX5-NCoR1 Single case Nuclear receptor corepressor [106]
PAX5-GOLGA6 Single case not known [106]
PAX5-TAOK1 Single case Serine/threonine kinase [106]
PAX5-MLLT3 Single case Component of the super elongation
complex
[128]
PAX5-CHFR Single case E3 ubiquitin-protein ligase [128]
PAX5-SOX5 Single case Transcription factor [128]
PAX5-POM121C Single case Component of the nuclear pore
complex
[128]
Follicular thyroid carcinoma PAX8-PPAR 30–35 Nuclear receptor Deregulation of PPARy
target genes
[129]
Follicular-variant papillary
thyroid carcinoma
PAX8-PPAR Recurrent Nuclear receptor Deregulation of PPARy
target genes
[83]
PAX5 fusions with fusion partner in reverse orientation or out of frame are depicted in italic.
lineage, PAX3 expression is generally downregulated upon differ-
entiation and PAX3-deregulation in cranial neural crest cells results
in developmental defects in the head region, suggesting that also in
neural crest cells PAX3 acts as upstream regulator of stemness and
differentiation [19]. In the mouse, PAX7 is also expressed in the cra-
nial neural crest, however its role in humans is less clear and PAX7
was not detected in the neural crest [20]. However, both PAX3 and
PAX7 expression was noted in a range of neuroectodermal tumors
such neuroﬁbroma (PAX3), malignant nerve sheet tumor (PAX3 and
PAX7), melanoma (PAX3), Ewing sarcoma (PAX3 and PAX7), medul-
loblastoma (PAX3) and primitive neuroectodermal tumor (PAX3)
[20].
2.1.2. PAX3 and PAX7 in alveolar rhabdomyosarcoma
Chromosomal translocations affecting PAX3 or PAX7 are asso-
ciated with development of alveolar rhabdomyosarcoma (aRMS).
ARMS represents a histological subgroup of rhabdomyosarcoma,
the most common soft tissue sarcoma in children. In 80% of aRMS
cases the PAX3 or the PAX7 gene are rearranged. In about 60%
of these a chromosomal translocation t(2;13)(q35;q14) gener-
ates the fusion protein PAX3-FOXO1, while a similar translocation
t(1;13)(p36;q14) associated with PAX7-FOXO1 is found in about
20% of cases [21]. In a small number of patients alternative fusions
including PAX3-FOXO4, PAX3-NCOA1, PAX3-NCOA2 and PAX3-
INO80D have been found [22–25] (Table 1). All fusion partners
have a role in transcriptional regulation. FOXO1 and −4 are tran-
scription factors, NCOA1 and −2 are nuclear receptor coactivators
and INO80D is a subunit of the INO80 chromatin remodeling
complex. In the fusion proteins, the DNA-binding domains of
the PAX protein are linked to the transcriptional transactiva-
tion domain of the fusion partner. Hence, the fusion proteins act
as aberrant transcription factors at PAX3 or PAX7 target genes.
High levels of fusion protein activity appear to be relevant for
aRMS development, with basal transcriptional activity of fusion
proteins being much higher than the one of the wildtype PAX
proteins [25,26]. Additional mechanisms further contribute to
boost their activity in aRMS, including gene ampliﬁcation in the
majority of PAX7-FOXO1 cases [27], copy-number independent
increase of transcriptional activity in case of PAX3-FOXO1 [28] and
increased protein stability [29,30]. Furthermore, negative regula-
tion by phosphorylation-induced sequestering of proteins into the
cytoplasm, a mechanism by which different kinases including Akt
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negatively affect the activity of all wildtype FOXO family members
[31–33], is not active in the context of the fusion protein. Probably
as a result of the dominating effect of the nuclear localization signal
present in the PAX N-terminus, the fusion proteins are perma-
nently localized in the nucleus [31]. Akt-mediated phosphorylation
might have a direct effect on PAX3-FOXO1 transcriptional activ-
ity depending on its strength, with low Akt signaling associated
with elevated PAX3-FOXO1 transcriptional activity and hyperac-
tivated Akt associated with repressed PAX3-FOXO1 activity [34].
These observations strongly suggest that the fusion proteins act by
deregulation of a PAX3 or PAX7 target gene signature. The PAX3/7-
FOXO1 dependent gene signature has been studied in the past
decade by several groups and contains several hundred mostly
upregulated genes [25,35–38], however, the relevance of the indi-
vidual genes for aRMS tumorigenesis is still only poorly understood.
The translocations are the main recurrent genetic aberrations found
in aRMS, which otherwise have a very low somatic mutation bur-
den, and are thought to be the ﬁrst genetic hit [23,39]. In a recent
genome sequencing study of a large cohort of aRMS tumors one
case was found having no protein-coding somatic alterations apart
from the PAX3-FOXO1 translocation and a copy number neutral
LOH on chromosome 11p [23]. Taken together, this suggests that
the PAX fusion proteins act as the major oncogenic drivers in
aRMS.
The cell (lineage) of origin of aRMS is still debated. Most fre-
quently, aRMS tumors are found in the extremities [40], but in
general they can appear throughout the body [40] even at sites
unexpected for a soft tissue sarcoma such as the bone marrow
[41–43]. Hence no clear association between primary tumor site
and tissue of origin exists. However, RMS  tumors in general are
characterized by expression of myogenic differentiation markers,
which is the basis for their naming. On the cytological level this
includes presence of (rare) cross-striated and multinucleated cells
[44] and on the molecular level expression of a range of skeletal
muscle speciﬁc marker proteins including skeletal muscle actin,
myosin, myoglobin, Z-band protein, MYOD and myogenin [45–47].
These features are reminiscent for an interrupted skeletal muscle
differentiation and have led to the hypothesis that RMS  originates
from the myogenic lineage. Uncontrolled high activity of the fusion
protein in a committed cell of the myogenic lineage might pre-
vent these cells from undergoing terminal differentiation and trap
them in a proliferative state. Indeed, different lines of evidence
support this hypothesis. First, silencing of the fusion protein by
siRNA in in vitro cultured aRMS cell lines induces, apart from cell
death, a strong upregulation of a range of muscle markers including
troponin C, troponin I, crystalline aB and myosin light and heavy
chain [38], suggesting that downregulation of the fusion protein
allows the cells to further execute the myogenic differentiation
program. Second, in in vitro transformation experiments it was
shown that expression of PAX3-FOXO1 in combination with hTERT
and NMyc can convert primary human myoblasts into tumorigenic
cells producing aRMS like tumors in mice [48]. Finally, conditional
expression of PAX3-FOXO1 during different stages of the myo-
genic lineage in combination with loss of p53 or Ink4a, induces
formation of tumors in mice [49,50]. Most susceptible for forma-
tion of tumors resembling human aRMS was found to be the fetal
myoblast stage (Myf6 lineage) [50]. Interestingly, normally Myf6 is
expressed in terminally differentiating myoblasts at stages where
PAX3 expression is already shut down, raising the provocative pos-
sibility that aRMS tumors originate from terminally-differentiating,
Myf6-expressing myoﬁbres [49]. In accordance with this ﬁnding is
data from a Drosophila model, where expression of PAX7-FOXO1 in
differentiated myoﬁbers can drive the generation of nucleated cells
[51]. Together, these data are consistent with a model in which the
fusion protein would be able to induce dedifferentiation toward a
stem cell state. Interestingly however, during embryogenesis Myf6
shows a biphasic expression pattern with a ﬁrst transient activation
in myotomes during somitogenesis and a second wave of expres-
sion in fetal skeletal muscle [52]. Myf6 expression in some cells of
the ventral thoracic somites is earlier than during myogenesis and
precedes expression of MyoD [53]. Such cells might represent an
alternative pool for tumor development upon PAX3-FOXO1 expres-
sion, without the necessity for reversal of differentiation [54].
A central mechanism by which the fusion protein might block
the differentiation process of the myogenic lineage might be inter-
ference with the activity of the MRFs, especially MyoD (for review
see [55]). PAX3-FOXO1 interferes with the activity of MyoD by dis-
turbing its capability to remodel the chromatin at its target gene
sites necessary for transactivation [56]. Interestingly, integrative
analysis of mutation and gene expression data from aRMS and
embryonal RMS  (eRMS), a related tumor also potentially originat-
ing from the myogenic lineage and similarly displaying a block in
the myogenic differentiation program, revealed a signiﬁcant over-
lap between PAX3(7)-FOXO1 target genes involved in growth factor
signaling in aRMS and genes mutated in eRMS. This suggests that
different mechanisms, having similar effects on differentiation, are
active in these two related tumor types with myogenic features
[23].
Importantly however, both in vitro and in vivo expression of
PAX3-FOXO1 alone was  not sufﬁcient to promote transformation
and tumorigenesis (tumor incidence in wildtype mice expressing
PAX3-FOXO1 was only 1/228). Other models conﬁrmed this ﬁnding
[57]. Hence, the fusion protein might not be the only genetic event
necessary for rhabdomyosarcomagenesis. However, loss of p53 or
Ink4a, which were used in the mouse models, are rarely found in
human aRMS [23,39], suggesting that these models might also have
caveats to consider. On the other hand it can not be excluded that
the myogenic expression pattern found in aRMS is rather a reﬂec-
tion of the activity of the fusion proteins themselves than of the
original transcriptome of the cell of origin. Forced expression of all
members of the MRF  familiy in cells of non-myogenic origin is able
to convert these cells into muscle cells [58–61]. Also PAX3 has the
ability to induce myogenic commitment, albeit only in speciﬁc cell
types, mainly of mesenchymal origin [62]. Along these lines, differ-
ent alternative cells of origins have been discussed. These include
pericytes/mesangioblasts [50] and mesenchymal stem cells (MSCs)
[63]. The latter hypothesis is based on the fact that in some aRMS
patients, both of the PAX3-FOXO1 and the PAX7-FOXO1 type, tumor
cells have been found exclusively in the bone marrow, without a
detectable primary tumor present elsewhere [41–43,64]. This sug-
gests that the bone marrow might not be a metatstatic but in fact
the primary site of tumor development. MSCs are present in most
postnatal tissues including the bone marrow and differentiate into
tissues of mesodermal origin such as adipocytes, osteoblasts or
skeletal myocytes [65]. Similar to the experiments performed with
human myoblasts, sole expression of PAX3-FOXO1 in mouse MSCs
did not transform these cells to a state capable to form xenograft
tumors in mice. However, in combination with cooperative events
such as presence of dominant-negative p53, xenograft tumors with
an aRMS like gene expression pattern did grow in mice [66].
The potential cell of origin might be an even less committed
cell like a neural crest cell. Interestingly, aRMS cells express a large
signature of neurogenesis-associated genes, at least some of them
target genes of PAX-FOXO1 [67], potentially reﬂecting the multipo-
tency of the cell of origin. Furthermore, AP2, a marker for neural
crest cells [68], is also highly expressed and used as marker for
aRMS, allowing discrimination from eRMS [69,70]. Potentially, even
more than one cell of origin could be involved. In this respect, it
is also not known whether PAX3-FOXO1 and PAX7-FOXO1 posi-
tive aRMS originate from the same cell of origin. On  the one hand
PAX3 and PAX7 have a very high sequence identity of 93 and 97%
in the paired box and homeobox domains, respectively, and it has
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been suggested that they originated during evolution by dupli-
cation of a common ancestral gene [71]. Indeed, replacement of
PAX3 by a PAX7 knock-in was shown to restore most of the func-
tions of PAX3 during embryonic development [72]. Therefore, it is
thought that they bind to a similar set of target genes. Comparison
of PAX3-FOXO1 and PAX7-FOXO1 gene expression data in aRMS
conﬁrmed that discriminating gene sets are small and not strictly
correlated to the two fusion genes [67]. On the other hand, PAX3
and PAX7 have distinct functions during development and also in
aRMS differences between PAX3-FOXO1 and PAX7-FOXO1 cases
have been described. Most importantly, the clinical outcome of
patients with PAX7-FOXO1 has been claimed by several studies to
be signiﬁcantly better when compared to PAX3-FOXO1 cases with
4–5 year overall survival rates of 74–92% (75% in case of metastatic
tumors) of patients with PAX7-FOXO1 tumors versus 35–64% (8%
in case of metastatic tumors) of patients with PAX3-FOXO1 tumors
[21,67,73,74], albeit in a European cohort such differences were
not detected [75]. Accordingly, compared to PAX7-FOXO1 positive
tumors, PAX3-FOXO1 positive aRMS are more often associated with
known adverse clinical risk-factors such as patient age higher than
10 years, tumor invasiveness and staging into poorer risk groups
[21,75,76]. Additionally, some biological features of tumor cells
have been found to differ between PAX3-FOXO1 and PAX7-FOXO1
aRMS tumors such as expression of markers for active cell cycle and
apoptosis [77].
Irrespective of the cell of origin however, it seems obvious that
PAX3 and PAX7 act early in the involved cell lineage(s) and that
uncontrolled upregulation of their activity in the context of the
fusion proteins blocks terminal differentiation of these cells.
2.1.3. PAX3 in biphenotypic sinonasal sarcoma
Recently, rearrangement of the PAX3 locus has also been found in
96% of biphenotypic sinonasal sarcoma (SNS) and in 79% of the cases
a fusion of PAX3 with MAML3  was involved [78]. MAML3  is one of
three structurally divergent Mastermind (MAM)  isoforms (MAML1,
MAML2  and MAML3), which act as transcriptional coactivators of
the Notch intracellular domain [79]. Only MAML1  and MAML3  are
essential for Notch signaling in vivo and their combined knock-out
is embryonically lethal in the mouse [80]. Similar to the fusion pro-
teins found in aRMS, also in PAX3-MAML3 the DNA binding part
of PAX3 is fused to the transactivation domain of the fusion part-
ner. Accordingly, also PAX3-MAML3 has a transcriptional activity
which is much higher than the one of wildtype PAX3.
SNS is a distinct spindle cell sarcoma found in the sinonasal
region of mainly middle aged adults, with women more frequently
affected than men  [81]. Also SNS show both neural and myogenic
features [81] and expression proﬁling conﬁrmed that the tumors
express genes involved in neuroectodermal and myogenic dif-
ferentiation [78]. However, transcriptome analysis demonstrated
that SNS clearly separate from aRMS tumors, highlighting that
sarcoma characteristics are dependent on different cooperative
parameters including cell of origin and characteristics of the fusion
protein. The cell of origin is not yet known for this tumor entity.
Nevertheless, the characteristics of SNS reﬂect the developmental
roles of PAX3 in the differentiation and migration of neural crest
cells and other cells of ectodermal and mesodermal lineage. Hence,
similar to the fusion proteins in aRMS, an important aspect of
the oncogenic activity of PAX3-MAML3 might be blocking of
differentiation and trapping these cells in a proliferative precursor
state.
2.2. PAX8 in thyroid cancer
While PAX8 protein is also expressed in the developing brain
and kidney, its major role lies in the development of the thy-
roid gland. Hence, the only abnormality in PAX8 knock-out mice
is the absence of a thyroid gland and in humans, PAX8 muta-
tions are the cause of congenital hypothyroidism [82]. The PAX8
gene is rearranged in about 30–35% of follicular thyroid carci-
nomas (FTC), some follicular-variant papillary thyroid carcinoma
and occasionally in follicular adenomas [83,84]. In these tumors
translocation t(2;3)(q13;p25) leads to fusion with the PPARG gene.
The corresponding protein PPAR- is a transcription factor of the
nuclear receptor family acting as master regulator of adipogenesis.
Endogenous ligands include fatty acids and eicosanoids [85]. In the
PAX8-PPAR- fusion a truncated part of PAX8 containing the DNA
binding domain but lacking part of the transactivation domain is
fused to full length PPAR-1· The fusion protein therefore has the
potential to affect both PAX8 and PPAR- target genes. A range
of in vitro studies using cultured thyrocytes demonstrated that
the fusion protein induces cell proliferation, blocks cell death and
permits anchorage-independent growth, typical for an oncogenic
behavior [86–88]. Again, in transgenic mice PAX8-PPAR- alone
is not sufﬁcient to induce tumor development, however expres-
sion in thyroid cells in combination with homozygous deletion of
Pten induced formation of thyroid carcinoma [89]. The functional
contributions of the two partners in the fusion are only partially
understood, however effects on expression of target genes of both
fusion partners might play a role. PAX8 target genes are variably
stimulated or repressed in PAX8-PPAR- transfected cells [86]. Sim-
ilarly, also PPAR- target genes are either stimulated or repressed.
Since it was  shown in in vitro studies that the fusion protein can
inhibit some properties of wildtype PPAR- it was postulated that
it might interfere with a potential tumor suppressive function of
PPAR-. However, in gene expression studies of FTC with and with-
out PAX8-PPAR- it was found that PPAR- target gene signatures
known from adipocytes are upregulated in the PAX8-PPAR- pos-
itive tumors [90,91]. To make it even more complex, treating the
transgenic mouse model with a PPAR- agonist had a strong anti-
tumor effect despite induction of many PPAR-  target genes in the
tumor cells [89].
Hence, the contribution of hijacked PAX8 and PPAR- functions
to tumorigenesis and especially their involvement in block of dif-
ferentiation of thyroid cancer cells needs further clariﬁcation.
3. Loss of function roles of PAX proteins in cancer
3.1. PAX5
3.1.1. PAX5 in normal B-cell development
In contrast to the oncogenic activities of the mutant forms of
PAX3, PAX7 and PAX8 described above, PAX5 acts as tumor sup-
pressor in the haematopoietic lineage. Reduction of its activity is
causally involved in tumorigenesis of some B-cell precursor acute
lymphoblastic leukemia (B-ALL).
PAX5 plays an important role in normal B-cell development [92].
B-cell development is a stepwise process that is initiated in the bone
marrow with the differentiation of hematopoietic stem cells (HSCs)
into lymphoid-primed multipotent progenitors (LMPPs) followed
by common lymphoid progenitors (CLPs) (Fig. 1). CLPs then give
rise to pre-pro-B cells, which subsequently differentiate into pro-B
cells, where commitment to the B cell lineage occurs [93] and Igh
recombination takes place. Successful Igh recombination leads to
expression of IgH on the cell surface, which together with surro-
gate light chain and accessory signaling molecules (Ig,  Ig)  forms
the pre-B cell receptor (pre-BCR) and characterizes the large pre-B
cell state. Activation of the pre-BCR induces a burst of proliferation
[94], activates recombination of the Igl locus and triggers differen-
tiation into the small pre-B cell stage. Successful rearrangement of
the Igl locus then leads to the expression of BCR and progression
to the immature B cell stage. These cells exit the bone marrow and
complete their development to the mature B cells in the periphery.
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At the molecular level, these hierarchical cellular changes are
controlled by a set of transcription factors that act in a complex net-
work to control the respective processes. PAX5 plays a central role
in this network. PAX5 is not required for the initial stages of B cell
development but its expression starts at the pro-B cell stage until it
is downregulated during antigen driven differentiation of mature B
cells into immunglobulin secreting plasma cells [95]. PAX5 is nec-
essary for the execution of the differentiation program in stages
following the pro-B cell state, based on its ability to repress B cell
lineage inappropriate genes. Consequently, in PAX5-deﬁcient mice
B-cell development is arrested at the pro-B cell stage [96]. In lieu
thereof, such PAX5-negative pro B-cells are able to differentiate into
different other hematopoietic cell types such as T cells or myeloid
cells [97]. The B cell lineage is characterized by some plasticity since
deletion of PAX5 even in mature B cells results in dedifferentiation
to pro-B cells and lymphomagenesis [98].
3.1.2. PAX5 in leukemia
PAX5 is mutated in about 40% of both childhood and adult pre-
cursor B-cell acute lymphoblastic leukemia (B-ALL) and in some
cases of chronic myelogenous leukemia (CML) at the time of
progression to acute leukemia blast crisis by a diverse set of mecha-
nisms [99–102]. Furthermore, germline hypomorphic mutations in
PAX5 are associated with B-ALL susceptibility, albeit additional loss
of the wildtype allele was always seen in such B-ALL cases [103]. The
most frequent aberrations found in about 30% of cases are monoal-
lelic deletions affecting the entire or part of the PAX5 gene, leading
to reduction of the expressed PAX5 protein [100]. Interestingly,
during the earliest phase of B cell commitment only a single allele of
PAX5 is transcribed, before expression switches to a bi-allelic mode
when B cells begin to differentiate [104]. It was speculated that loss
of one allele therefore might interfere with the ability of the cell to
increase expression levels by inducing bi-allelic expression [100].
A second type of mutation found in about 5–7% of cases are point
mutations that affect the DNA-binding or transcriptional regulatory
domains of the protein which result in lost or altered DNA-binding
or transcriptional activity of the protein. Finally, in 2–3% of cases
translocations involving the PAX5 gene have been found generat-
ing different chimaeric PAX5-fusion proteins [100,101,105]. PAX5
fusion partners are a very heterogeneous group of genes includ-
ing transcription factors, structural proteins and kinases (Table 1).
In some cases out of-frame fusions, fusion with a gene in oppo-
site direction and fusion with non-coding sequences have been
described which can lead to generation of truncated proteins as
a result of premature stop codons [106]. Importantly however, and
similar to the structure of PAX fusion proteins found in other can-
cers, all described PAX5 fusion proteins retain the paired domain
and most also octapeptide and nuclear localization signal of PAX5,
suggesting that they bind to DNA and negatively inﬂuence the activ-
ity of wildtype PAX5 on target gene expression. Indeed, competitive
reporter assays performed with some of the fusion proteins includ-
ing PAX5-ELN, PAX5-ETV6 or PAX5-FOXP1 demonstrated that these
fusion proteins act as competitive inhibitors of wildtype PAX5
[100,107]. Interestingly however, some of the fusion proteins were
recently found to retain some transcriptional activity, inducing
transcription at least from the PAX5-responsive CD79A promoter
in a reporter assay [108]. Furthermore, for PAX5-JAK2 [109] and
for PAX5-ETV6 ectopically expressed in mouse pre-B cells [110],
it was claimed that the fusion not simply antagonizes PAX5 func-
tion but inﬂuences expression of PAX5 targets in a more complex
manner, potentially also activating some PAX5 target genes in the
endogenous context. Finally, the PAX5 fusion partner might also
exert additional effects beyond the PAX5 target gene signature
that play a role in tumorigenesis (Table 1). In case of PAX5-PML
the fusion protein has been shown to inhibit sumoylation of wild-
type PML, and thereby interferes with PML  nuclear body formation,
which is associated with increased resistance to apoptosis [111].
In case of the PAX5-JAK2 fusion, the JAK2 part is able to activate
the JAK-STAT pathway, leading to induction of a STAT expression
signature, suggesting that JAK2 inhibitors might be a therapeutic
option for tumors with this type of fusion protein [109]. Altogether,
this suggests that the different PAX5 fusion proteins might exert
distinct effects in B-ALL. Their mode of action might go beyond
pure reduction of PAX5 activity as it is the case in the tumors with
monoallelic loss of the PAX5 gene. In accordance with such a model,
most of the cases with a monoallelic deletion of PAX5 display a
complex karyotype and are associated with some of the classic
recurrent translocations found in ALL such as BCR-ABL (frequency
among B-ALL 2–4%), TCF3-PBX (2–6%), ETV6-RUNX1 (15–25%) and
IGH translocation (2–3%), however not with MLL  rearrangements
(6%), suggesting that the PAX5 deletion is a secondary event in
some of these tumors and appears rather late in the oncogenic
process, potentially in subclones of the tumor [102,106,112,113].
In contrast, in cases with PAX5 fusion proteins or PAX5 truncated
proteins, the PAX5 rearrangement was mostly the sole gross chro-
mosomal abnormality, suggesting that such an event occurs earlier
in the oncogenic process [106], similar to PAX3/7 rearrangements.
Overall, the data strongly suggests that PAX5 acts as tumor
suppressor in B-ALL. It supports a model where haploinsufﬁcient
reduction of PAX5 activity in an early B-cell stage disables further
B cell differentiation, which then cooperates with other aberrations
in development of B-ALL. This conclusion is further supported by
the fact that apart from PAX5 other genes coding for transcriptional
regulators of lymphoid development including IKZF1,  IKZF3, LEF1,
TCF3, and EBF1, the latter two  direct regulators of PAX5 expres-
sion, are also frequently affected by loss-of-function mutations or
deletions in B-ALL (together with PAX5 in two-thirds of all cases)
suggesting that block of B-cells in certain precursor states is a gen-
eral mechanism relevant for tumorigenic transformation of cells in
the B-cell lineage [100].
However, details of the tumorigenic process are not clear
yet. Pro-B cells have the capacity for self-renewal and unlimited
in vitro proliferation when cultured on stroma in presence of IL-
7 [114,115]. In accordance, the most common subtype of B-ALL
with 60–65% of cases is early pre-B-ALL (pro-B), suggesting that
a block at this proliferative stage often contributes to human B-
ALL leukemogenesis [116]. However, in B-ALL also other stages of
B-cell development are represented, with the pre-B form of ALL
accounting for 20–25% and mature B-cell leukemia accounting for
2–3% of ALL. PAX5 aberrations have been found in all these stages
[102]. This suggests that the situation in the context human B-
ALL is more complex and not one-to-one comparable with mouse
knock-out models. Such differences might also explain why  PAX5
heterozygous mice have a normal B-cell development [117], while
in development of B-ALL loss of approximately half of the PAX5
activity blocks differentiation of these cells [118]. However, since
loss of PAX5 is only one among several tumorigenic events neces-
sary for development of B-ALL, reduction of PAX5 activity might
affect the cell differentiation more efﬁciently in an aberrant state.
Different mouse models have been generated to study the con-
tribution of PAX5 loss to B-ALL leukemogenesis. Similar to the
other PAX proteins described here, heterozygosity of PAX5 alone
is not sufﬁcient to induce tumor formation in mice [119]. However,
in a transgenic B-ALL model driven by hematopoietic expression
of constitutively active STAT5, which alone induces B-ALL with
a relatively long latency and low penetrance of 1–2% [120], loss
of one allele of PAX5 dramatically accelerated leukemia forma-
tion in 100% of the animals [119]. Importantly, and comparable to
human tumors, the wildtype allele of PAX5 was unaffected in this
model, demonstrating a similar haploinsufﬁciency mode of action.
In a similar mouse model combining constitutively active STAT5
with reversible RNAi-mediated silencing of PAX5, it was  found that
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even brief restoration of PAX5 expression in leukemia cells causes
rapid cell cycle exit and disables their leukemia-initiating capac-
ity [118]. Phenotypic and transcriptomic analysis demonstrated
that this differentiation response closely mimics the transition of
large cycling pre-B cells to small resting pre-B cells found in nor-
mal  hematopoiesis [118]. In the same study also the human B-ALL
cell lines REH, 697 and NALM-6 were found to be addicted to PAX5
hypomorphism. Hence, these ﬁndings not only causally link loss
of PAX5 with B-ALL initiation but demonstrate that reduced PAX5
levels are also relevant for tumor maintenance.
4. Conclusions
Taken together, the data demonstrate that inappropriate PAX
protein activity is involved in tumorigenesis of different malig-
nancies. The described mutations in PAX proteins are involved in
blocking differentiation of the affected cells and keeping them in a
proliferative state. It has been suggested that the most permissive
state for pro-tumorigenic effects of mutations in a cell lineage is the
transit-amplifying/progenitor stage [121]. At this stage cells divide
rapidly, which allows for their exponential expansion. Deregula-
tion of PAX protein activity might be causally involved in the block
of the exit from such a stage in cancer cells.
Both loss of function and gain of function mechanisms have been
identiﬁed and lead to the following model (Fig. 1): PAX proteins
with a potential for oncogenic behavior upon activation by muta-
tion are normally active in the proliferative state of a cell lineage
and have to be downregulated before differentiation of the cells
proceeds. Prime examples for this group are PAX3 and PAX7 in alve-
olar rhabdomyosarcoma. In contrast, PAX proteins with a tumor
suppressor activity are necessary for the exit from the proliferative
state of a cell linage and remain expressed during (part of) the dif-
ferentiation process. Their reduction or loss therefore blocks cells
in a progenitor state. Prime example for this group is PAX5 in the
B-cell lineage and B-ALL.
The exact stage of the affected lineages at which the mutations in
the PAX proteins have to appear is not clear yet. However, data from
mouse models of both aRMS and B-ALL suggest that a certain plas-
ticity in the affected cell lineages exists, even allowing reversion of
cells from a relative late stage of the lineage to a more proliferative
state early in the lineage upon inappropriate PAX protein activity.
Whether there is a “point of no return” in the differentiation hier-
archy after which these mutations are no longer tumorigenic, is not
yet clear.
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